NVO Stock Price and Chart — NYSE:NVO

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

Novo Nordisk ended its partnership with Hims & Hers on June 23, 2025, over marketing allegations, causing a 5.5% drop in its stock, while Hims & Hers fell over 26%.

Novo Nordisk partners with WeightWatchers to improve access to its weight-loss drug, Wegovy, from July 1, offering easier prescriptions and lifestyle support via CenterWell Pharmacy.

Wegovy, containing semaglutide, is projected to lose patent protection in India by 2026, which may lead to increased competition from other companies developing similar products.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.